ASTH vs BWMN: stock comparison and AI forecast
Astrana Health, Inc. (ASTH) and Bowman Consulting Group Ltd. (BWMN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ASTH Astrana Health, Inc.
- Price
- $39.01 +8.1% · 6M
- Market Cap
- $2.17B
- P/E Ratio
- 58.2x
- Size
- mid-cap
- AI Forecast
BWMN Bowman Consulting Group Ltd.
- Price
- $43.00 +23.7% · 6M
- Market Cap
- $745M
- P/E Ratio
- 81.1x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ASTH is 2.9 times larger than BWMN by market capitalization ($2.17B against $745M).
- ASTH trades at 58.2 times trailing earnings, BWMN at 81.1 times.
- Over the last six months BWMN returned +23.7% and ASTH +8.1%.
- BWMN turns 1.4% of its revenue into net income, against 1.1% for ASTH.
- ASTH carries 2.03 times debt per unit of equity, against 1.42 times for BWMN.
- ASTH yields 0.77% in dividends; BWMN pays none.
- Both companies share the SEC industry classification Services-Management Consulting Services.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ASTH | BWMN |
|---|---|---|
| Market Cap | $2.17B | $745M |
| P/E Ratio | 58.22x | 81.11x |
| P/B Ratio | 2.62x | 2.91x |
| Dividend Yield | 0.77% | – |
| EPS | $0.67 | $0.53 |
| Book Value/Share | $14.90 | $14.80 |
| Revenue/Share | $68.97 | $30.43 |
| FCF/Share | $1.69 | $0.72 |
Profitability & Margins
| Metric | ASTH | BWMN |
|---|---|---|
| ROE | 4.9% | 2.9% |
| ROA | 1.8% | 1.2% |
| ROIC | 6.5% | 4.9% |
| Gross Margin | 10.5% | 53.4% |
| Operating Margin | 2.6% | 3.3% |
| Net Margin | 1.1% | 1.4% |
| EBT Margin | 1.6% | 0.7% |
| Tax Rate | 34.7% | -96.0% |
Financial Health
| Metric | ASTH | BWMN |
|---|---|---|
| Current Ratio | 1.23x | 0.90x |
| D/E Ratio | 2.03x | 1.42x |
| Financial Leverage | 2.75x | 2.42x |
| Interest Coverage | 2.4x | 2.3x |
| Working Capital | $172M | -$26M |
Cash Flow
| Metric | ASTH | BWMN |
|---|---|---|
| Operating Cash Flow | $108M | $23M |
| Free Cash Flow | $94M | $13M |
| Capital Spending | -$13M | -$11M |
| OCF Growth YoY | -17.4% | -33.6% |
| FCF Growth YoY | -22.2% | -62.9% |
| FCF/Sales | 2.5% | 2.4% |
| CapEx/Sales | 0.3% | 2.0% |
Operational Efficiency
| Metric | ASTH | BWMN |
|---|---|---|
| Asset Turnover | 1.68x | 0.85x |
| Receivables Turnover | 8.3x | 3.8x |
| Fixed Assets Turnover | 61.4x | 22.2x |
| Days Sales Outstanding | 44 days | 97 days |
| Payables Period | 5 days | – |
Income Statement
| Metric | ASTH | BWMN |
|---|---|---|
| Total Revenue | $3.84B | $528M |
| Operating Income | $100M | $18M |
| Net Income | $41M | $7M |
| SG&A Expense | – | $235M |
| Cost of Goods Sold | $3.44B | $246M |
Dividend & Shareholder Information
| Metric | ASTH | BWMN |
|---|---|---|
| Dividends Per Share | $0.30 | – |
| Payout Ratio | 44.8% | – |
| Shares Outstanding | 56M | 17M |
| Net Income Growth | 60.5% | -32.6% |
| EPS Growth | -2.9% | -17.2% |
ASTH vs BWMN: stock comparison and AI forecast
Which is bigger, ASTH or BWMN?
ASTH is 2.9 times larger than BWMN by market capitalization ($2.17B against $745M).
Which is cheaper on earnings, ASTH or BWMN?
ASTH trades at 58.2 times trailing earnings, BWMN at 81.1 times.
Which stock performed better over the last six months, ASTH or BWMN?
Over the last six months BWMN returned +23.7% and ASTH +8.1%.
Which one does Intratio's AI model rank higher, ASTH or BWMN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.